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Abstract
Background: Systemic inflammation is linked to cardiovascular risk, but the influence of persistent pathogens,
which are conventionally dichotomously categorized, on circulating levels of inflammatory markers is not clear.
Antibody levels of pathogens have not been examined in relation to inflammation.
Methods: Using data from a subsample of the Multi-Ethnic Study of Atherosclerosis, we examined circulating
levels of interleukin-6 (IL-6), C-reactive protein (CRP) and fibrinogen in relation to five common persistent
pathogens: cytomegalovirus, herpes simplex virus-1, Hepatitis A virus, Helicobacter pylori and Chlamydia
pneumoniae. We tested the hypothesis that the number of seropositive pathogens (based on conventional cut-off
points) would not be as sensitive a marker of inflammation as immune response measured by antibody levels to
pathogens.
Results: High antibody response to multiple pathogens showed graded and significant associations with IL-6 (p <
0.001), CRP (p = 0.04) and fibrinogen (p = 0.001), whereas seropositive pathogen burden did not. In multiple linear
regression models, high antibody response to multiple pathogens maintained a positive association only with IL-6
(4.4% per pathogen exhibiting high antibody response, 95% CI 0.0-8.9).
Conclusions: High antibody response to pathogens was a more consistent marker of inflammatory outcomes
compared to seropositivity alone and high antibody response to multiple pathogens was a stronger marker
compared to any single pathogen.
Background
Persistent pathogens, those acquired early in life and
maintained without causing obvious illness, are impli-
cated in cardiovascular disease etiology. Numerous stu-
dies have suggested that persistent viruses such as
cytomegalovirus (CMV), herpes simplex virus-1 (HSV),
Hepatitis A virus (HAV) and bacterial pathogens such
as Helicobacter pylori (H. pylori) and Chlamydia pneu-
moniae (C. pneumoniae) are associated with cardiovas-
cular disease [1-4], although some studies do not
support a significant relationship [5-7]. Effects of
multiple infectious agents may be synergistic, and some
authors suggest that pathogen burden (total number of
pathogens) has a greater impact on cardiovascular risk
than isolated pathogens [4,8,9]. It is hypothesized that
the association between pathogens and cardiovascular
disease is, in part, mediated through chronic activation
of inflammatory pathways [10,11].
In parallel to work linking chronic infections to ather-
osclerosis, a number of studies have shown that various
markers of systemic inflammation are linked to cardio-
vascular risk. Cytokines such as interleukin-6 (IL-6)
induce the production and secretion of acute-phase pro-
teins including C-reactive protein (CRP) and fibrinogen
[12,13]. Chronic activation of these inflammatory path-
ways is hypothesized to promote atherogenesis and
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thrombosis [14]. Levels of IL-6 [15,16], CRP [17-19] and
fibrinogen [20] show consistent associations with inci-
dent coronary events and subclinical disease indepen-
dent of established cardiovascular risk factors. A
number of risk factors for chronic inflammation (includ-
ing smoking [21], physical activity [22], and obesity [23])
have been identified. However, the influence of persis-
tent pathogens on circulating levels of inflammatory
markers is unclear and existing studies have been incon-
sistent [24-26].
We used data from a large population-based sample to
examine associations between infectious agents and
inflammatory pathways implicated in cardiovascular dis-
ease in healthy adults. We examined circulating levels of
IL-6, CRP and fibrinogen in relation to the presence of
and antibody response to five pathogens: CMV, HSV,
HAV, H. pylori and C. pneumoniae. We hypothesized
that the conventional definition of pathogen burden
(number of seropositive pathogens using conventional
cut-off points) would not be as sensitive a marker of
inflammation as an alternative definition also taking into
account antibody levels of pathogens.
Methods
Study sample
The Multi-Ethnic Study of Atherosclerosis (MESA) is a
population-based longitudinal study designed to investi-
gate risk factors for atherogenesis. Study participants
(n = 6814), aged 45 to 84 years, were recruited from six
US communities and were free of clinical cardiovascular
disease at the time of the baseline visit from July 2000
to September 2002. The current cross-sectional analysis
uses data on C. pneumonia from the total cohort at
baseline, and from a sub-sample of 1000 randomly
selected cohort members who underwent serum testing
for additional pathogens implicated in cardiovascular
disease (CMV, HSV, HAV and H. pylori). Complete
information including data on all infectious agents,
inflammatory markers and covariables was available for
999 individuals. The Institutional Review Board at each
participating site reviewed the study and written
informed consent was collected from all participants.
Detailed methods and aims of the MESA cohort are
available [27].
Data
During the baseline visit, a range of sociodemographic,
behavioral and anthropometric variables were collected.
Data included education categorized into four groups
(less than high school, high school diploma or equiva-
lent, some college or technical school and college
diploma); body mass index (BMI, kg/m2) to define over-
weight or obesity status as ≥ 25 kg/m2; current alcohol
intake; pack-years of cigarette smoking, current use of
medications known to alter inflammatory levels (any
one or more of the hormone replacement therapies,
aspirin, oral anti-inflammatory agents, lipid-lowering
drugs and non-steroidal anti-inflammatory drugs,
grouped into a single dichotomous variable); and self-
rated health measured on a scale of 1 (best) to 5
(worst); 1-3 were considered “good self-rated health”.
Lab tests
Serum IgG antibodies to CMV, HSV, and H. pylori,
were measured by indirect enzyme immunoassay using
commercially available kits (DiaMedex Corp. Miami,
FL). The sensitivity and specificity of the tests ranged
from 94-100%. Hepatitis A antibody was measured
using the IMx HAVAB qualitative microparticle enzyme
immunoassay (Abbott Laboratories, Abbott Park, IL).
Immunoglobulin G antibodies to C. pneumoniae were
detected using a microimmunoflourescent antibody
assay with a range of 0-4 Microimmunofluorescence
(MIF) units (Focus Technologies, Cypress, CA). Conven-
tional cut-off points were used to define dichotomous
seropositivity; equivocal values were classified as posi-
tive. Individuals were considered seropositive for CMV
infection above 10.0 EU/mL, HSV infection above 16.0
EU/mL, HAV below a standardized calibrated rate, and
H. pylori infection above 0.90 EU/mL [28]. Infection
with C. pneumoniae was considered positive at 1 MIF
unit or higher. We defined ‘high antibody response’ to
pathogens as IgG values in the top quartile (lowest
quartile for HAV). For C. pneumoniae, titer groups 3-4
were considered high antibody response.
Interleukin-6 (pg/mL) was measured by ultrasensitive
ELISA (R&D Systems, Minneapolis, MN). CRP (mg/L)
and fibrinogen (mg/dL) were assessed by nephelometry
(BNII nephelometer, Dade Behring, Deerfield, IL). Ana-
lytic coefficients of variation were 6.3%, 2.6%, and 3.6%
for IL-6, fibrinogen, and CRP, respectively.
Statistical methods
Descriptive analyses were carried out using chi-squared
tests (for trend where applicable). Kruskal-Wallis rank
tests were performed for descriptive variables with
skewed distributions. The dependent variables were cir-
culating levels of IL-6 in pg/mL, CRP in mg/L and fibri-
nogen in mg/dL. Interleukin-6 and CRP presented
skewed distributions and were log-normalized prior to
analysis. Independent variables took two forms: 1) sero-
positive pathogen burden, defined as the count sum of
seropositive pathogens using conventional cut-off points
(0-5 pathogens with groups 0-1 collapsed for some ana-
lyses); and 2) high antibody response to multiple patho-
gens, defined as the count sum of pathogens with
antibody response in the highest quartile (high antibody
response to 0-5 pathogens, groups 3-5 collapsed for
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some analyses). We first examined associations of inter-
leukin-6 (IL-6), C-reactive protein (CRP) and fibrinogen
with dichotomous measures of high antibody response
to each pathogen and second, with the number of
pathogens for which there was a high response (0-5).
We performed the same analysis using conventional
cut-offs for seropositivity to each pathogen and the
number of seropositive pathogens.
Tetrachoric (for dichotomous variables) correlation
coefficients were calculated to investigate correlations
between the different dependent variables and one-way
ANOVA was used to test for differences in inflamma-
tory levels according to levels of markers. Linear regres-
sion was used to estimate adjusted associations of
seropositivity and high antibody levels with inflamma-
tory markers. Four levels of covariate adjustment were
used in regression models: 1) adjusted for age and sex;
2) adjusted for age, sex and race/ethnicity; 3) adjusted
for age, sex, race/ethnicity and education; and 4) adjusted
for all of the above plus body mass index, current
alcohol intake, cigarette smoking (pack-years), diabetes,
current use of medication and self-rated health.
Results
The mean age of the sample was 59 years (range 44-84),
with 46% white, 21% black, 23% Hispanic and 10%
Chinese. Women comprised 57% of the sample. Eighteen
percent had finished high school but had no college edu-
cation and 29% and 37% of participants had some college
education or completed college, respectively. Mean (SD)
BMI was 28.6 kg/m2 (5.6) and 72% were overweight or
obese. Almost 90% rated their health as good.
Nearly 77% of the sample was seropositive for CMV,
85% for HSV, 58% for HAV, 46% for H. pylori, and 71%
for C. pneumoniae. Less than 2% of the sample was
negative for all five of the tested pathogens, whereas
51% were seropositive for either four or five. Tetrachoric
correlation coefficients for seropositivity among patho-
gens ranged between 0.42-0.55 except for those invol-
ving C. pneumoniae, which were weaker and on the
order of 0.12-0.24. All were statistically significant at the
p < 0.05 level. Median (IQR) levels for IL-6, CRP, and
fibrinogen were 1.12 pg/mL (0.72-1.74), 2.00 mg/L
(0.82-4.59), and 340 mg/dL (296-391), respectively.
Table 1 shows the distribution of sociodemographic
and health characteristics of the 999-participant sample
according to number of seropositive pathogens. There
was a positive trend of increasing age by number of
pathogens. Non-whites and less educated individuals
had higher seropositive pathogen burden (both p <
0.001). Alcohol consumption was associated with lower
seropositive pathogen burden, as was self-rated good
Table 1 Mean (SD) or percent sociodemographic and health characteristics according to seropositive pathogen burden
in a sub-sample of the Multi-Ethnic Study of Atherosclerosis (2000-2002)
Number of seropositive pathogens P value*
0-1 2 3 4 5
Age, y 56.8 (8.4) 59.1 (9.7) 59.5 (10.0) 59.9 (10.1) 59.9 (9.6) 0.02
Female 54.6 54.6 58.5 59.4 56.1 0.8
Race/ethnicity <0.001
White 21.6 28.8 26.6 14.8 8.3
Black 2.9 10.1 23.4 34.0 29.7
Hispanic 1.7 3.9 12.9 35.3 46.1
Chinese 1.0 1.0 16.2 35.4 46.5
Education <0.001
<High school 0.0 1.2 15.1 34.9 48.8
Finished high school 5.7 11.3 20.3 27.7 35.0
Some college 8.4 16.8 25.5 26.6 22.7
College graduate 20.7 25.3 22.6 19.6 12.0
BMI, kg/m2 28.1 (5.4) 27.9 (5.3) 28.8 (6.1) 28.4 (5.5) 28.6 (5.7) 0.2
Smoking, pack years 12.2 (30.6) 10.0 (17.1) 18.4 (30.1) 9.8 (18.8) 8.0 (14.4) 0.03
Alcohol consumer 84.6 73.3 61.8 48.8 44.4 <0.001
Diabetic 6.4 8.6 7.4 15.6 14.6 0.006
Self-rated good health 95.4 93.6 90.9 85.1 78.1 <0.001
N 110 163 217 256 253 –
Pathogens examined:
*P-values by chi-squared test. (sex, race/ethnicity, education, alcohol use, diabetes, self-rated health), chi-square test for trend (age and BMI), and Kruskal-Wallis
test (pack-years of smoking).
BMI: body mass index, kg/m2.
Alcohol consumer: alcoholic drink within the past week.
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health, whereas smoking and diabetes were associated
with a higher pathogen burden.
Table 2 shows inflammatory marker levels by seropo-
sitivity and level of antibody response to each pathogen.
Seropositivity for individual pathogens was associated
with higher inflammatory levels for 11 of the 15 tested
associations (all except HAV with CRP and fibrinogen;
H. pylori with CRP; and C. pneumoniae with fibrinogen),
although only one (HSV with fibrinogen) was significant
(p = 0.006). HAV infection was significantly associated
with fibrinogen as well, but inversely. High antibody
response to multiple pathogens, on the other hand, was
consistently associated with higher inflammatory levels
across all markers, although only four (CMV with all
three markers and C. pneumonia with IL-6) were
significant.
Figures 1 and 2 show unadjusted inflammatory levels
by seropositive pathogen burden and high antibody
response to multiple pathogens, respectively. Seroposi-
tive pathogen burden was associated with higher circu-
lating levels of IL-6 and fibrinogen but the associations
were of borderline significance (p = 0.07 and 0.05 for
Table 2 Inflammatory marker levels by seropositivity and high antibody response to each pathogen in a sub-sample
of the Multi-Ethnic Study of Atherosclerosis (2000-2002)
Pathogen Seropositivity* or
antibody response†
N IL-6, pg/mL CRP, mg/L Fibrinogen,
mg/dL
Cytomegalovirus Negative 227 1.07 (1.04) 1.90 (1.08) 345 (75)
Positive 758 1.18 (1.02) 2.01 (1.05) 349 (73)
P-value - 0.06 0.5 0.5
Q1-Q3 510 1.13 (1.03) 1.83 (1.06) 344 (75)
Q4 249 1.31 (1.04) 2.44 (1.08) 360 (69)
P-value - 0.004 0.002 0.002
Herpes simplex virus-1 Negative 150 1.05 (1.05) 1.67 (1.10) 333 (65)
Positive 835 1.18 (1.02) 2.04 (1.04) 351 (75)
P-value - 0.05 0.06 0.006
Q1-Q3 600 1.15 (1.03) 2.02 (1.05) 350 (78)
Q4 248 1.24 (1.04) 2.09 (1.08) 353 (68)
P-value - 0.2 0.7 0.4
Hepatitis A virus Negative 425 1.14 (1.03) 2.02 (1.06) 353 (76)
Positive 574 1.17 (1.03) 1.95 (1.05) 342 (70)
P-value - 0.6 0.7 0.02
Q2-Q4 319 1.13 (1.04) 1.85 (1.07) 348 (73)
Q1 255 1.21 (1.04) 2.10 (1.08) 357 (79)
P-value - 0.2 0.2 0.2
H. pylori Negative 531 1.13 (1.03) 1.99 (1.06) 347 (76)
Positive 454 1.18 (1.03) 1.97 (1.06) 350 (72)
P-value - 0.3 0.9 0.5
Q1-Q3 215 1.17 (1.04) 1.96 (1.09) 347 (69)
Q4 246 1.20 (1.04) 1.98 (1.08) 352 (74)
P-value - 0.7 0.9 0.5
C. pneumoniae Negative 288 1.14 (1.04) 1.90 (1.08) 349 (77)
Positive 697 1.16 (1.02) 2.02 (1.05) 347 (72)
P-value - 0.6 0.5 0.7
T1-T2 534 1.12 (1.03) 1.99 (1.05) 346 (72)
T3-T4 175 1.32 (1.06) 2.11 (1.11) 353 (72)
P-value - 0.005 0.6 0.2
Presented as geometric mean (SE) for IL-6 and CRP; mean (SD) for fibrinogen.
Q1-Q4 represents lowest through highest quartiles for all pathogens except C. pneumoniae.
T1-T4 represents titer groups for C. pneumoniae.
P-values by one-way ANOVA.
*Cut-offs for seropositive status: cytomegalovirus≥ 8.0 Elisa Units (EU)/mL; herpes simplex virus-1 ≥ 16.0 EU/mL; hepatitis A virus, rate≤ 200; H. pylori≥ 0.90 EU/
mL; C. pneumoniae≥ 1.0 Microimmunofluorescence (MIF) units.
†High antibody response defined as top quartile of antibody response to pathogen (lowest quartile for hepatitis A virus) and titer groups 3-4 for C. pneumoniae.
Low-intensity defined as bottom three quartiles to pathogens and titer groups 0-2 for C. pneumoniae..
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trend, respectively). There was no association with CRP.
The examination of associations of high antibody levels
with inflammatory markers revealed stronger patterns.
Levels of IL-6 (p < 0.001), CRP (p = 0.04) and fibrino-
gen (p = 0.001) were all significantly and positively asso-
ciated with high antibody response to multiple
pathogens.
Table 3 shows percent differences in inflammatory
markers associated with both methods of assessing
pathogen burden; seropositive pathogen burden and
high antibody response to multiple pathogens, respec-
tively, in four sequentially adjusted models. Positive
associations between seropositive pathogen burden and
IL-6 and fibrinogen were modest in model 1 and not
statistically significant in adjusted models. In contrast,
high antibody response to multiple pathogens was posi-
tively and significantly associated with IL-6, CRP and
fibrinogen in model 1, with a 2 to 9% increase in inflam-
matory marker level per pathogen exhibiting a high anti-
body response. Estimates weakened with further
adjustment, but associations with IL-6 remained statisti-
cally significant after adjustment for age, sex, race/
ethnicity, and education (approximately 4% increase per
pathogen exhibiting a high antibody response; model 3).
Associations were reduced and no longer statistically
significant when further adjusted for BMI, behavioral,
and health variables (model 4).
Interactions of sex and race with pathogen burden
(according to seropositivity or high antibody response)
revealed no consistent patterns.
Discussion
This is among the first studies to evaluate the relation-
ship between pathogen burden based on conventional
cut-offs for seropositivity and high antibody response as
potential correlates of multiple markers of inflammation.
We found that high antibody response was a more con-
sistent marker of inflammatory outcomes than seroposi-
tivity alone. Previous work has generally not
differentiated between seropositivity and antibody
response [29], but our results suggest that this may be
an important distinction. Earlier studies showed similar
associations with inflammation in many of the patho-
gens examined here, suggesting that our results are
Figure 1 Levels of interleukin-6 (IL-6), C-reactive protein (CRP) and fibrinogen by seropositive pathogen burden in a sub-sample of
the Multi-Ethnic Study of Atherosclerosis (2000-2002). P values for trend by linear regression.
Figure 2 Levels of interleukin-6 (IL-6), C-reactive protein (CRP) and fibrinogen by high antibody response to multiple pathogens in a
sub-sample of the Multi-Ethnic Study of Atherosclerosis (2000-2002). P values for trend by linear regression.
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compatible with population based estimates [8,26,30-32].
Also in line with previous findings, sociodemographic
and health indices were significantly associated with
number of seropositive pathogens [28,33-35]. There are
less data, however, showing the relationships between
sociodemographic characteristics and antibody response
in population based studies in the US.
Testing of persistent pathogens often relies on enzyme
linked immunosorbent assays (ELISA). These assays
provide a qualitative assessment of the amount of anti-
body in a serum sample. Clinical studies are generally
concerned with whether or not individuals tests positive
for IgM or IgG to the pathogen of interest and rarely
provide data on the qualitative antibody response identi-
fied in the ELISA test. Our findings regarding associa-
tions of antibody response with inflammation suggests
that the qualitative data obtained from an ELISA is an
important variable given that this measure predicts
inflammation levels. Our findings suggest that antibody
levels among the infected, rather than seropositivity is a
better marker of inflammatory levels.
Pathogen burden (number of seropositive pathogens)
was more strongly associated with inflammation than
was any one individual pathogen and seropositivity to
pathogens was highly correlated. Pathogen burden has
been implicated in cardiovascular disease in several dif-
ferent study populations [33,36]. It has been suggested
that pathogen burden may not only be a predictor of
coronary complications, as previously described, but that
it may also be associated directly with the development
of atherosclerotic plaques [24]. Zhu and colleagues have
suggested that inflammation is one pathway by which
these associations are linked [8]. Prasad et al. found that
pathogen burden and CRP levels interacted significantly
such that carriers of 4-5 pathogens and elevated CRP
levels (> 0.5 mg/dL) had higher odds of coronary artery
disease compared to those with fewer pathogens [4],
supporting the notion that pathogen burden along with
inflammation has a stronger impact than any one patho-
gen alone or inflammation alone. A recent study showed
that antibody levels to one of the pathogens we exam-
ined here, CMV, was associated with an increased rate
of cardiovascular mortality among aging individuals
[37]. No previous studies have examined the impact of
high antibody response to multiple pathogens on inflam-
matory outcomes.
We found that associations of antibody levels with
IL-6 were more consistent than associations with the
other inflammatory markers. In addition, associations
with IL-6 persisted after adjustment for age, race and
socioeconomic factors but were reduced and no longer
statistically significant after adjustment for potential
mediators of inflammation such as smoking and obesity.
Limited sample size, as well as strong associations
between antibody levels and variables such as BMI and
smoking may have hampered our ability to detect asso-
ciations after multiple adjustments. Larger studies are
needed to determine whether associations are indepen-
dent of other risk factors.
There are several possible pathways by which high
antibody response to multiple pathogens could impact
inflammation more strongly than seropositivity alone.
Infection with a particular pathogen may not strongly
influence a disease process whereas a strong immune
Table 3 Percent difference in inflammatory markers associated with increasing seropositive pathogen burden* and
increasing number of pathogens exhibiting high antibody response† in a sub-sample of the Multi-Ethnic Study of
Atherosclerosis (2000-2002)
Method Inflammatory marker Model 1 Model 2 Model 3 Model 4
Seropositive pathogen burden* IL-6 2.2 (-0.9,5.3) 0.7 (-2.9,4.4) -1.4 (-5.0,2.4) -2.6 (-6.0,0.9)
CRP 1.4 (-4.1,7.2) 0.5 (-5.9,7.3) -2.0 (-8.4,4.9) -4.2 (-10.1,2.0)
Fibrinogen 0.7 (-0.3,1.6) -1.2 (-2.3,0.0) -1.6 (-2.7,-0.5) -1.7 (-2.8,-0.6)
High antibody response to multiple pathogens† IL-6 9.3 (4.9,13.8) 5.8 (1.5,10.3) 4.4 (0.0,8.9) 1.7 (-2.4,6.0)
CRP 8.0 (0.2,16.4) 4.3 (-3.3,12.5) 2.2 (-5.3,10.4) -0.2 (-7.3,7.4)
Fibrinogen 2.0 (0.7,3.3) 0.7 (-0.6,2.0) 0.4 (-0.9,1.8) 0.2 (-1.1,1.5)
*Seropositive pathogen burden: seropositivity to 0-5 pathogens analyzed as a continuous variable.
†High antibody response to multiple pathogens: high antibody response to 0-5 pathogens analyzed as a continuous variable.
Coefficient (95% CI) shows the percent difference in inflammatory marker level per additional seropositive pathogen or per additional pathogen exhibiting a high
antibody response.
Model 1 adjusted for age and sex.
Model 2 adjusted for age, sex and race/ethnicity.
Model 3 adjusted for age, sex, race/ethnicity and education.
Model 4 adjusted for all of the above plus body mass index, alcohol intake, smoking (pack years), diabetes, medications, self-rated health.
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response to that pathogen may. Rheumatic heart disease
is an example of this phenomenon whereby the immune
response to the pathogen (and ensuing inflammation) is
the relevant disease process, rather than the infection
itself [38]. In the case of infections occurring early in
life and persisting over time (likes several of the patho-
gens we studied); a higher initial infectious dose may
lead to a more vigorous antibody response at a young
age which is maintained over the life course for persis-
tent infections. Since persistent infections are generally
acquired early in life [39], the long term effects of high
antibody response may lead to chronically higher levels
of inflammation. However, it is not clear why individuals
exhibit differentials in antibody response to pathogens.
Recent work has indicated that lower socioeconomic
position and exposure to chronic stressors may lead to a
higher antibody response to CMV, HSV, and H. pylori
[28,40]. Indeed, there are several experimental studies
that have demonstrated significant relationships between
exposure to psychosocial stressors and a high antibody
response to persistent herpes virus (see Herbert and
Cohen 1993 for review). Thus, a number of host charac-
teristics may influence antibody response to an infec-
tion. Additional studies are needed to better understand
the mechanisms by which antibody response may influ-
ence systemic inflammation over the life course.
Some methodological considerations of this study war-
rant mention. Relatively small sample sizes may have
affected our ability to detect associations with all mar-
kers. The inflammatory outcomes we tested could have
been influenced by a number of factors that were not
measured or measured imprecisely, even though care
was taken to account for several potentially inflamma-
tory conditions and medications that may impact
inflammation. Our models also did not account for
recent or current acute inflammatory states, such as
those associated with the common cold, which may
have impacted our findings. Antibody and biomarker
levels were only measured once and intra-individual var-
iation cannot be accounted for. However, assay variabil-
ity would be expected to bias findings towards the null
so the observed associations are potentially underestima-
tions. Also, IgG antibody response provides data on past
infection- we did not examine data on recent infection
or DNA shedding of the viruses and cannot assess
whether individuals were experiencing reactivation of
the infection. The cross-sectional nature of this analysis
precludes implications of causality, and specifically, we
cannot rule out the possibility that higher inflammatory
status may have led to higher levels of antibodies via
activation of the immune response. Four racial/ethnic
groups were represented in our data, adding an impor-
tant strength to our study; however, findings may not be
representative of other ethnic or age groups. Finally, it is
important to note that viral and bacterial infectious
agents may act through different mechanistic pathways
to impact inflammation, but assessment of alternative
biological pathways, such as infection residing within
the cardiovasculature, was beyond the scope of this
cross-sectional observational study.
Conclusions
In summary, high antibody response to multiple patho-
gens emerged as a better marker of inflammation com-
pared to seropositivity status alone. Our findings suggest
that future studies should consider including antibody
response data in addition to seropositivity classification
of pathogens. Technological advances for refining mea-
surement of antibody response for persistent pathogens
is an important endeavor and may reduce measurement
error in this potentially important biomarker. Opportu-
nities for further research also include examination of
the mechanistic pathways by which antibody response
to pathogens contributes to inflammation as well as to
cardiovascular disease and its correlates.
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